·OÀÙ°©Å讽ÃØ ¬O§U¤H¡HÁÙ¬O®`¤H¡H ¡]http://37tcm.wordpress.com/2009/04/21/%E6%85%88%E6%BF%9F%E9%AA%A8%E9%AB%93%E6%8D%90%E8%B4%88-%E6%98%AF%E5%8A%A9%E4%BA%BA%EF%BC%9F%E9%82%84%E6%98%AF%E5%AE%B3%E4%BA%BA%EF%BC%9F/ ¡^

Posted on 2009/04/21 by 37tcm

«á¾Ç¤@ª½»{¬°¡A°µ¦n¨Æ¤£¦p°µ¹ïªº¨Æ¡A¦n¨Æ¦³®É¤£¤@©w¬O¹ïªº¨Æ¡C®½°©Åè¬O§U¤H¡H
®`¤H¡H¤£§«¬Ý¬Ý¥H¤U¤å³¹¡C

¼gµ¹·OÀÙ®v©jªº¤@«Ê«H

¿Ë·Rªº·OÀÙ®v©j¡A¤]³\©p¤£»{ÃѧڡA¦ý¬O§Ú­Ì¦³¤@­±¤§½t¡A«Ü©êºp¼g³o¤@«Ê«Hµ¹±z¡A¦³¨Ç¨Æ±¡§Ú·QÅý©pª¾¹D¡C

¨º¤Ñ¡Aª¿¨¦ªº·OÀÙ¤¤¤å¾Ç®Õ¿ì·s¬K¶é¹C·|¡A¨C¤@­Ó¯Z¯Å³£¦³¦Û¤v¯Z¤WªºÅu¦ì¡C¥H©¹ªº¶é¹C·|¡A¦Y¦Y³Ü³ÜªºÅu¦ì³Ì¦h¡A¤pªB¤Í¤]«Ü³ßÅw¡A¦ý¬O¨C¦¸¦Y§¹¡A©U§£±í¸Ìº¡º¡ªº§K¬~À\¨ã¡A¦n¤£®ö¶O¡C¤µ¦~¥D¿ì³æ¦ì¨M©w¡A¤£¯à¦A¦³½æ¦YªºÅu¦ì¡A©Ò¥H¤µ¦~³£¬Oª±¤@¨Ç¤p¹CÀ¸ªºÅu¦ì¡A²{³õ¤]«D±`¼ö¾x¡C§Ú¤@¤â²oµÛ¨à¤l¡A¤@¤â²oµÛ¤k¨à¡A¨«¶i¤F¼ö¾x¯M¯Mªº·|³õ¡C

¦b·|³õªº¤@¨¤¡A§Ú¬Ý¨ì¤F©p­ÌªºÅu¦ì¡A¤j¤jªº¦rÅý¤H«ÜÃø¤£¬Ý¨ì¡A¡u·OÀÙ¥\¼w·|°©Å讽ÃØ¡v¡C§Ú¤ßÀY¤@»þ¡A¨º¹Ð«Ê¤w¤[ªº©¹¨Æ¥ß¨è¯B¤W¤ßÀY¡A¤U·NÃѪº¡A§Ú±aµÛ¨à¤l¦V¥t¤@Ã䨫¥h¡C©p¬Ý¨ì§Ú¤F¡A§Ú¤ß¸Ìª¾¹D¡A©p¦b¦V§Ú¨«¹L¨Ó¡C©pº¡Áy¯º®e¡A§Ú§CµÛÀY·Q°kÁסCÁÙ¬O³Q©pÄd¦í¤F¡C

©p­¢¤£¤Î«Ýªº§i¶D§Ú¤°»ò¥s¥Õ¦å¯f¡A¦h»ò¥i©Èªº¥Õ¦å¯f¡A¤j¤H¡B¤p«Ä¡BÀ¦¨à¡B¦Ñ¤H¡B¦~»´¤H³£·|±o¨ì¡C©p¶ëµ¹§Úªº¤p¥U¤l¤W¡A¦LµÛ¤@±i±i¯íµMªºÁy¤Õ¡C©p§i¶D§Ú¡A¥L­Ì °ß¤@ªº§Æ±æ¡A´N¬O°©Åè²¾´Ó¡A°ß¦³°©Åè²¾´Ó¤~¯à±Ï¥L­Ìªº©R¡C¦b©pªº²´¸Ì¡A§Ú¬Ý¨ì¤F¤@­Ó·OÀÙ¤Hªº¯u¸Û¡A©p°J¤ßªº§Æ±æ§Ú¯à¥[¤J°©Å讽Ãتº¸ê®Æ®w¡C©p§i¶D§Ú¡A³s¦å³£¤£¥Î©â¡A¥u­n¥Î¤@­Ó´Öªá´Î¡A¦b¤fµÄ¤º°¼¨í¤@¤U´N¦n¡A¤@ÂI³£¤£·|µh¡C§Ú¹ï·OÀÙ¤H¡AÁ`¬O¦³µÛ±R°ªªº·q·N¡A¨ØªA¦o­Ìªº±¡¾Þ¡A¦b¦h¦¸ªº±ÏÃø¬¡°Ê¤¤¡A¬ÝµÛ·OÀÙ¤H¦b ¶¤¥î¤¤¦£¸L¡A§ÚÁ`¬O¤Q¤À·P°Ê¡C

¥i¬O¡A³o¦¸§Ú¨S¦³·P°Ê¡C

®v©j¡A©p¥iª¾¹D¡A§Ú¬Ý¹Lªº¥Õ¦å¯f¤H¡A¤ñ°_©p¨Ó¡A¤£ª¾¦h¤F¦h¤Ö¡C¥Õ¦å¯f¤H¹ï©p¨ÓÁ¿¡A¥i¯à¥u¬O­Ó¦Wµü¡A¦ý¬O¡A¹ï§Ú¨Ó»¡¡A«o¬O¤@³õ²`¨èªº¦^¾Ð¡C§Ú¤£¤î¬Ý¹L¡AÁÙ³­¤F«Ü¦h¤H¡A¨«¹L¤F¥L­Ì¥Í©R¤¤ªº³Ì«á¤@¬q¸ô¡C©p±À¼sªº°©Åè²¾´Ó¡A§Ú¤]´¿¸g¬Û«H¡A¦ý¬O¡A¦b¬Ý¹L¤@­Ó­Ó¥¢±Ñªº¨Ò¤l«á¡A§Ú¨S¦³¿ìªk¦A¬Û«H¡C

©pª¾¹D°©Åè²¾´Ó¬O¦p¦ó¶i¦æªº¶Ü¡H¦b¤d¨¯¸U­W§¹¦¨°©Åè°t¹ï¤§«á¡A§â¯f¤Hªº°©Åè©â¥X¨Ó¡A§â®½Ãت̪º©ñ¶i¥h¡A³o¼Ë´N§¹¦¨¤F¶Ü¡H¿ù¤F¡A¬°¤F©È¯f¤H¿ò¯d¦b¨­Å骺°©Å褤¤´µM¦³¡uÃa¡vªº¥Õ¦å²y¡A¦b°©Åè²¾´Ó¤§«e¡A¯f¤H­n§@¥þ¨­¤j¾¯¶qªº¤ÆÀø¡A¥[¤W©ñÀø¡A¤]´N¬O­n°í¾À²M³¥¡A¤£¯d¤U¥ô¦ó¤@­ÓÃa¥÷¤l¡C³o­Ó¹Lµ{¤¤¡A¦nªºÃaªº¦å²y³q³q±þ¥ú¡AµM«á¦A§â®½Ãتº°©Åè©ñ¶i¨Ó¡C¦¹®É¡A¯f¤H¤@©w«D±`µê®z¡A¥²¶·¦b¹jÂ÷¯f©Ð¦í¤W«Üªøªº¤@¬q¤é¤l¡Aµ¥«Ý¦å²yªº­««Ø¡C³o­Ó¹Lµ{¤¤¡A¥ô¦ó¤@­Ó¦W¤£¨£¸g¶Çªº¤p²Óµß¡A ³£¯à­n¤F¯f¤Hªº©R¡A¦]¬°¯f¤Hµ¥©ó¥þ¤£³]¨¾¡A¨­¤W¨S¦³¤@ÂI¨¾¿mªº¯à¤O¡C§Ú»{ÃѪº¥Õ¦å¯f¤H¡A³£¬O¦b³o­Ó¶¥¬q·P¬V«á¡AÂ÷¶}¤H¥@¡C

©È©p¤£¬Û«H¡A§Ú¦bºû°ò¦Ê¬ì§ä¤F¸ê®Æ¡A¨Ó¦õÃÒ§Úªº»¡ªk¡C

http://en.wikipedia.org/wiki/Bone_marrow_transplantation

Autologous HSCT requires the extraction (Apheresis) of haematopoietic stem cells (HSC) from the patient and storage of the harvested cells in a freezer. The patient is then treated with high-dose chemotherapy with or without radiotherapy with the intention of eradicating the patient¡¦s malignant cell population at the cost of partial or complete bone marrow ablation (destruction of patient¡¦s bone marrow function to grow new blood cells). The patient¡¦s own stored stem cells are then returned to his/her body, where they replace destroyed tissue and resume the patient¡¦s normal blood cell production. Autologous transplants have the advantage of lower risk of infection during the immune-compromised portion of the treatment since the recovery of immune function is rapid. Also, the incidence of patients experiencing rejection (graft-versus-host disease) is very rare due to the donor and recipient being the same individual. These advantages have established autologous HSCT as one of the standard second-line treatments for such diseases as lymphoma.[9] However, for others such as Acute Myeloid Leukemia, the reduced mortality of the autogenous relative to allogeneic HCST may be outweighed by an increased likelihood of cancer relapse and related mortality, and therefore the allogeneic treatment may be preferred for those conditions.[10]

¤]³\©p·|»¡¡A¤£ºÞªvÀøªº¹Lµ{¦p¦ó§xÃø¡A¦³®ÄªG´N­È±o¥h§@¡A§Ú¦P·N¡A¨º»ò¦¨¥\ªº¼Æ¾Ú¦b­þ¸Ì©O¡H§Ú§ä¤F¤S§ä¡A¦b·OÀÙªººô¯¸¤W³£§ä¤£¨ì©ú½Tªº¸ê®Æ¡A©pÁ`¸Ó§i¶D§Ú¨ì©³¦³´X¨Ò¦¨¥\ªº®×¨Ò§a¡H§Ú²×©ó§ä¨ì¤F³o­Ó¡G

How to Understand NMDP Transplant Center Statistics

ùØ­±©p¥i¥H¬Ý¨ì¥þ¬ü¦U­ÓÂåÀø¾÷ºcÃö©ó°©Åè²¾´Óªº²Î­p¸ê®Æ¡C³oùظê®Æ«Ü¦h¡A§Ú­Ì´N¨Ó¬Ý¬ÝÆW°Ï³ÌµÛ¦Wªº¥v¤¦ºÖ¤j¾Çªºªþ³]Âå°|§a¡I

Stanford Hospital and Clinics
Blood and Marrow Transplant Program
Center-Specific Analysis

This analysis is based on transplants performed from Jan. 1, 2002 through Dec 31, 2006, using unrelated NMDP donors. It only includes patients who were confirmed to be either alive or deceased within one year of transplant.

1.      This center reported survival status data for 184 patients.

2.      The overall disease condition of patients treated at this center was in the low category (1 on a scale of 1 to 5).

3.      The actual one-year survival of these patients was 62.4%.

4.      The predicted one-year survival was 61.0% (with 95% statistical confidence that the predicted survival was between 54.4% and 68.1%).

5.      This center¡¦s actual results are similar to the predicted range for this center. National one-year estimated actual survival was 54.0% in the 8,847 patients transplanted in the United States.

³o­Ó¸ê®Æ«Ü¦³½ì¡A±q2002¨ì2006Á`¦@¤­¦~¡A§@¤F184¦ì¯f¤H¡C³o­Ó¤ÀªR³£¬O¥H¦¨¥\ªº¤è¦V¨Ó³ø¾É¡AÅý§Ú¥Î¥t¥~¤@­Ó¤è¦V¨Ó¸ÑÄÀ¡G

¡P         ²Ä¤T±ø©M²Ä¥|±øªº·N«ä¬O¡A¦pªG¯f¤H§@°©Åè²¾´Ó¡A¤@¦~¤§¤º¬ù¦³¤@¥bªº¾÷·|¡A¯f¤H·|¥á¤F©Ê©R¡C

¡P         ²Ä¤T±ø·t¥Ü»¡¡A²Ä¤@¦~¥H«á¡A¯f¤H¥á±¼©Ê©Rªº¾÷·|¡A±N·|¤j38%¡]100% ¡V 62.4%)¡C ¬Æ¦Ü§Ú¥i¥H±À´ú¡A¨â¦~ªº¦s¬¡²v¡A±N»·¤p©ó62.4%¡C±z»¡¬O¶Ü¡H¦pªG¨â¦~ªº¦s¬¡²v¤ñ³o­Ó¤j¡A¨º¬°¤°»ò³o½g¤ÀªR±qÀY¨ì§À³£¥u»¡¤@¦~¤ºªº¦s¬¡²v©O¡H

¡P         °²³]¨C¦~³£¦³50%ªº¾÷²v¯f¤H·|¥á¤F©Ê©R¡A¨º»ò¤T¦~ªº¦s¬¡²v±N¬O¡G12.5% (50% * 50% * 50%)

³o¼Ë¤l¨Óºâ¡A´N«Ü±µªñ§Ú¦b¥x¤jÂå°|ªº¸gÅç¤F¡C½Ð°Ý­þ¸Ì¥i¥H¬Ý¨ì·OÀÙªº¼Æ¾Ú©O¡H¦pªG¦¨¥\ªº¾÷²v¬O¤@¥b¡A¨º¤£´«°©Åè¡B¤£§@¤ÆÀø¡A¯à¤£¯à¹F¨ì¤@¦~¤º62.4%ªº¦s¬¡²v©O¡H

©Ò¥H¡A¿Ë·Rªº·OÀÙ®v©j¡A§Ú¯uªº¤£·Q®½°©Åè¡C

by ¬W¤l

¤å³¹¨Ó·½¡G ¼gµ¹·OÀÙ®v©jªº¤@«Ê«H (§@ªÌ¬°°õ·~¤¤Âå®v)¡C

­ì¤å¤¤ªº¬õ¦â¦r§ï¬°¾ï¦â¦r¡A¦Ó¬õ¦â¦r¬°«á¾Ç©Ò¼Ð°O¡C